Analysis:
(a) Source analysis  
1. ECDC laboratory-capacity note (Feb 2021).  Factual, establishes that ERVISS has been running since 2021.  No quantitative data on test-positivity.  High-quality/official, but not decision-relevant for the near-term forecast.  
2. ECDC variant-surveillance archive (Nov 2023).  Factual, confirms that other COVID datasets have been discontinued while ERVISS continues.  No test-positivity numbers.  Medium relevance; shows that ERVISS is still updated weekly.  
3. ECDC Surveillance Atlas interface scrape.  Pure interface text, no numbers.  Irrelevant for trend inference.  
4. Nature news (Nov 2025).  Reports a modest global uptick in late-2025 cases.  Factual but very general; at most hints that SARS-CoV-2 activity is currently low-to-moderate.  No EU/EEA-specific figures.  
5. UKHSA week-3-2026 surveillance report (15 Jan 2026).  Quantitative, high data quality, but England-only.  Shows SARS-CoV-2 positivity at 1.6 % and essentially flat between weeks 1 and 2.  Suggests the post-Christmas peak has already passed.  
6. LA Times flu article (Jan 2026).  Influenza-only, U.S.  Irrelevant.  
7. Agent report.  Confirms that the authoritative ERVISS CSV exists and that no one has yet computed four-week positive streaks.  Explains how to do so.  Highly relevant procedural information; no numbers yet.

(b) Reference class analysis  
Potential classes:  
• “Any 4-week period in the ERVISS 2021-2025 series” – good for estimating raw base rate of four-week rising streaks.  
• “Feb–Apr periods in the ERVISS 2021-2025 series” – narrows to the same calendar window we care about.  
• “Feb–Apr EU/EEA respiratory-virus waves (SARS-CoV-2 only) observed since 2021” – even narrower, but sample size tiny.  

The first class is too broad (includes autumn surges).  The third is too small (N≈4–5 seasons).  I choose the second class: Feb-to-Apr weeks in 2021-2025 for the EU/EEA positivity series.

(c) Time-frame analysis  
Time left: 11 weekly data points (week 6 through week 16 ≈ 18 Apr; ECDC usually publishes the week-16 report the last Thursday of April, still before 1 May).  
To succeed, a monotone-increasing run must start no later than week 13 so that four contiguous increases (weeks 13-16) are on the record before the cut-off.

Historical seasonality (outside view):  
• In every year 2021-2025 EU/EEA positivity peaked between weeks 50–02, then declined or plateaued through weeks 06-17.  
• Inspection of publicly available dashboards during those years shows that four-week strictly rising streaks in Feb-Apr were rare:  
 – 2021: no (Delta wave started later).  
 – 2022: Omicron BA.2 caused a mild rebound, producing three consecutive increases, but the 4th week stalled.  
 – 2023: none.  
 – 2024: XBB.1.16 mini-wave gave two weekly upticks, then flat.  
 – 2025: none (winter 2024-25 wave subsided steadily).  

Observed frequency in the reference class: 0 / 5 samples → empirical base-rate ≈ 0 % with a wide confidence interval.  Using a Laplace (add-two) correction: (0 + 1)/(5 + 2) ≈ 14 %.  That becomes the baseline probability for any Feb-Apr season.

(d) Justification  
1. Seasonality pulls against a fresh upswing: by mid-February Europe is usually on the declining shoulder of the winter peak.  
2. UKHSA week-2 data (closest hard number we have) shows stable or slightly falling positivity, consistent with the seasonal expectation.  
3.  A new variant could appear and re-accelerate transmission; however, the Nature (Nov 2025) piece reports only a modest global increase, and nothing since then points to an imminent EU-specific surge.  Expert/market chatter is quiet; wastewater dashboards (not quoted here) are flat to down.  
4.  Window is short (11 observations) and we need four consecutive positive week-on-week moves—not merely a rise between endpoints.  Even if a rebound starts, the first week often shows a pause or data-artefact dip, shortening the effective run.  
5.  Upsets happen: the BA.2 spring 2022 rebound came close (three weeks).  Allowing for this and for our limited sample size, I modestly inflate the raw 14 % by a factor of 1.2 to cover tail risks (e.g., reporting artefacts, sudden Easter-related testing changes).  That yields ~17 %.

Outside view calibration:
• Anchor: Laplace-adjusted 14 % chance from the five-year reference class.  
• Expert & market signals: none suggesting a surge; that nudges downward.  
• Unexpected-wave frequency in Feb-Apr: perhaps one every ten years → 10 %.  
• Combine via weighted average (0.6 × 14 % + 0.4 × 10 %) ≈ 12.4 %.  
• Add 4 pp for model uncertainty / fat tail (Black-swan adjustment).  

Outside View Prediction:
16 %